Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Applied Immune Sciences

  • News

Executive Summary

CELLector CD5/8 and CD8 devices for leukemia and renal cell carcinoma, respectively, have not yet entered Phase III trials, AIS reports. "The Pink Sheet" (Nov. 21, p. 9) incorrectly reported the development status of the products. Both devices have "completed successful Phase I/II trials," AIS states, and "we anticipate beginning Phase III trials in both these areas; however, these Phase III trials have not yet begun"

CELLector CD5/8 and CD8 devices for leukemia and renal cell carcinoma, respectively, have not yet entered Phase III trials, AIS reports. "The Pink Sheet" (Nov. 21, p. 9) incorrectly reported the development status of the products. Both devices have "completed successful Phase I/II trials," AIS states, and "we anticipate beginning Phase III trials in both these areas; however, these Phase III trials have not yet begun".
Table

View full table

Tags:
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS025428

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By